Prof. Dr. med. Silke Gillessen Sommer
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
Templeton A, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P, Aebersold R, Klingbiel D, Gillessen Sommer S, Müller B, Winterhalder R, Stenner F, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013; 64:150-8.
06.04.2013Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
06.04.2013Eur Urol 2013; 64:150-8
Templeton Arnoud, Schiess Ralph, Wild Peter J, Rüschoff Jan H, Thalmann George, Dietrich Pierre-Yves, Aebersold Ruedi, Klingbiel Dirk, Gillessen Sommer Silke, Müller Beat, Winterhalder Ralph, Stenner Frank, Dutoit Valérie, Cathomas Richard, Rothermundt Christian, Bärtschi Daniela, Dröge Cornelia, Gautschi Oliver, Borner Markus, Fechter Eva, Swiss Group for Clinical Cancer Research (SAKK)
Multidisciplinary care in patients with prostate cancer: room for improvement
Strebel R, Winterhalder R, Morant R, Pless M, Huber U, Fehr M, Gillessen Sommer S, Schmid H, Sulser T, Cathomas R. Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer 2013; 21:2327-33.
26.03.2013Multidisciplinary care in patients with prostate cancer: room for improvement
26.03.2013Support Care Cancer 2013; 21:2327-33
Strebel Räto T, Winterhalder Ralph, Morant Rudolf, Pless Miklos, Huber Urs, Fehr Martin, Gillessen Sommer Silke, Schmid Hans-Peter, Sulser Tullio, Cathomas Richard
Angioedema in a renal cell cancer patient treated with everolimus in combination with an ACE inhibitor
Rothermundt C, Gillessen Sommer S. Angioedema in a renal cell cancer patient treated with everolimus in combination with an ACE inhibitor. J Clin Oncol 2013; 31:e57-8.
10.02.2013Angioedema in a renal cell cancer patient treated with everolimus in combination with an ACE inhibitor
10.02.2013J Clin Oncol 2013; 31:e57-8
Rothermundt Christian, Gillessen Sommer Silke
Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor
Rothermundt C, Gillessen Sommer S. Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor. J Clin Oncol 2013; 31:e57-8.
07.01.2013Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor
07.01.2013J Clin Oncol 2013; 31:e57-8
Rothermundt Christian, Gillessen Sommer Silke
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
Laurent J, Gnad-Vogt U, Stupp R, Quaratino S, Sessa C, Omlin A, Beck J, Gallerani E, Liedert B, Ongarello S, Bertrand C, Vicari M, Joffraud M, Gillessen Sommer S, Touvrey C, Speiser D. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med 2013; 11:5.
07.01.2013T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
07.01.2013J Transl Med 2013; 11:5
Laurent Julien, Gnad-Vogt Ulrike S, Stupp Roger, Quaratino Sonia, Sessa Cristiana, Omlin Aurelius, Beck Joachim, Gallerani Elisa, Liedert Bernd, Ongarello Stefano, Bertrand Caroline, Vicari Manuela, Joffraud Magali, Gillessen Sommer Silke, Touvrey Cedric, Speiser Daniel E
2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
Gillessen Sommer S, Fléchon A, Stoiber F, Kollmansberger C, Germa-Lluch J, Horwich A, Zucali P, Gross-Goupil M, Bachner M, Oechsle K. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012; 23:59-64.
13.12.20122-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
13.12.2012Ann Oncol 2012; 23:59-64
Gillessen Sommer Silke, Fléchon A, Stoiber F, Kollmansberger C, Germa-Lluch JR, Horwich A, Zucali PA, Gross-Goupil M, Bachner M, Oechsle K
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 2012; 18:6049-57.
12.09.2012Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
12.09.2012Clin Cancer Res 2012; 18:6049-57
Cathomas Richard, Gillessen Sommer Silke, von Moos Roger, Schiess Ralph, Pless Miklos, Berthold Dominik R, Siciliano Daniele, Winterhalder Ralph, Droege Cornelia, Cotting Denise, Brauchli Peter, Betticher Daniel C, Jaggi Rolf, Bubendorf Lukas, Klingbiel Dirk, Rothermundt Christian, Swiss Group for Clinical Cancer Research SAKK
Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
Schoenewolf N, von Moos R, Schraml P, Gillessen Sommer S, Ochsenbein A, Simcock M, Moch H, Mihic-Probst D, Dummer R, Swiss Group for Clinical Cancer Research (SAKK). Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. Case Rep Oncol 2012; 5:280-9.
05.06.2012Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
05.06.2012Case Rep Oncol 2012; 5:280-9
Schoenewolf Nicola L, von Moos Roger, Schraml Peter, Gillessen Sommer Silke, Ochsenbein Adrian, Simcock Mathew, Moch Holger, Mihic-Probst Daniela, Dummer Reinhard, Swiss Group for Clinical Cancer Research (SAKK)
[Inhibitors of androgen and estrogen biosynthesis in castration-resistant prostate cancer]
Omlin A, Gillessen Sommer S. [Inhibitors of androgen and estrogen biosynthesis in castration-resistant prostate cancer]. Urologe A 2012; 51:8-14.
01.01.2012[Inhibitors of androgen and estrogen biosynthesis in castration-resistant prostate cancer]
01.01.2012Urologe A 2012; 51:8-14
Omlin Aurelius, Gillessen Sommer Silke
[Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations]
Hartmann M, Krege S, Souchon R, De Santis M, Gillessen Sommer S, Cathomas R, Interdisziplinäre Arbeitsgruppe Hodentumore. [Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations]. Urologe A 2011; 50:830-5.
01.07.2011[Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations]
01.07.2011Urologe A 2011; 50:830-5
Hartmann M, Krege S, Souchon R, De Santis M, Gillessen Sommer Silke, Cathomas R, Interdisziplinäre Arbeitsgruppe Hodentumore
Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome
Kaelin M, Krek W, Aebersold R, Cerny T, Templeton A, Wild P, Powles T, Fankhauser N, Schiess R, Cima I, Gillessen Sommer S. Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome. Eur Urol 2011; 60:1235-43.
29.06.2011Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome
29.06.2011Eur Urol 2011; 60:1235-43
Kaelin Martin, Krek Wilhelm, Aebersold Ruedi, Cerny Thomas, Templeton Arnoud, Wild Peter, Powles Tom, Fankhauser Niklaus, Schiess Ralph, Cima Igor, Gillessen Sommer Silke
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer S, Loriot Y, Gross-Goupil M, Zucali P, Horwich A, Germa-Lluch J, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2011; 23:59-64.
02.04.20112-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
02.04.2011Ann Oncol 2011; 23:59-64
Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer Silke, Loriot Y, Gross-Goupil M, Zucali P A, Horwich A, Germa-Lluch J-R, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M
Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients
Souchon R, Hartmann M, Krege S, Lorch A, Mayer F, De Santis M, Gillessen Sommer S, Beyer J, Cathomas R. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol 2011; 187:158-66.
21.02.2011Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients
21.02.2011Strahlenther Onkol 2011; 187:158-66
Souchon Rainer, Hartmann Michael, Krege Susanne, Lorch Anja, Mayer Frank, De Santis Maria, Gillessen Sommer Silke, Beyer Jörg, Cathomas Richard
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
Cima I, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen Sommer S, Aebersold R, Leippold T, Fuchs T, Schubert O, Schiess R, Wild P, Kaelin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Krek W. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci USA 2011; 108:3342-7.
07.02.2011Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
07.02.2011Proc Natl Acad Sci USA 2011; 108:3342-7
Cima Igor, Wyler Stephen, Zehetner Jens, Jochum Wolfram, Buhmann Joachim, Cerny Thomas, Moch Holger, Gillessen Sommer Silke, Aebersold Ruedi, Leippold Thomas, Fuchs Thomas, Schubert Olga, Schiess Ralph, Wild Peter, Kaelin Martin, Schüffler Peter, Lange Vinzenz, Picotti Paola, Ossola Reto, Templeton Arnoud, Krek Wilhelm
Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients
Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F, De Santis M, Gillessen Sommer S, Interdisziplinäre Arbeitsgruppe Hodentumore. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie 2011; 34:59-64.
17.01.2011Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients
17.01.2011Onkologie 2011; 34:59-64
Cathomas Richard, Hartmann Michael, Krege Susanne, Souchon Rainer, Lorch Anja, Mayer Frank, De Santis Maria, Gillessen Sommer Silke, Interdisziplinäre Arbeitsgruppe Hodentumore
Das Prostatakarzinom im Wandel. Grundpfeiler der Diagnostik, Behandlung und Interdisziplinarität
Cathomas R, Berthold D, Gillessen Sommer S, Recker F, Stenner F, Strebel R, Sulser T, Zwahlen D, Schmid H. Das Prostatakarzinom im Wandel. Grundpfeiler der Diagnostik, Behandlung und Interdisziplinarität. Schweiz Med Forum 2011; 11:759-63.
01.01.2011Das Prostatakarzinom im Wandel. Grundpfeiler der Diagnostik, Behandlung und Interdisziplinarität
01.01.2011Schweiz Med Forum 2011; 11:759-63
Cathomas R, Berthold D, Gillessen Sommer Silke, Recker F, Stenner F, Strebel RT, Sulser T, Zwahlen DR, Schmid Hans-Peter
Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer
Gillessen Sommer S, Templeton A, Marra G, Kuo Y, Valtorta E, Shahinian V. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst 2010; 102:1760-70.
10.11.2010Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer
10.11.2010J Natl Cancer Inst 2010; 102:1760-70
Gillessen Sommer Silke, Templeton Arnoud, Marra Giancarlo, Kuo Yong-Fang, Valtorta Emanuele, Shahinian Vahakn B
Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib
Powles T, Peters J, Boleti K, Nathan P, Wilson P, Sadev A, Sarwar N, Lim L, Saunders N, Gillessen Sommer S, Bazeos A, Shamash J, Chowdhury S, Agrawal S. Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib. Ann Oncol 2010
13.10.2010Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib
13.10.2010Ann Oncol 2010
Powles T, Peters J, Boleti K, Nathan P, Wilson P, Sadev A, Sarwar N, Lim L, Saunders N, Gillessen Sommer Silke, Bazeos A, Shamash J, Chowdhury S, Agrawal S
Metastasiertes Prostatakarzinom – Behandlungsmöglichkeiten nach der Hormontherapie
Omlin A, Kaelin M, Templeton A, Jungi M, Gillessen Sommer S, Graf H, Rothermundt C. Metastasiertes Prostatakarzinom – Behandlungsmöglichkeiten nach der Hormontherapie. Swiss Medical Forum 2010; 10:483-485.
14.07.2010Metastasiertes Prostatakarzinom – Behandlungsmöglichkeiten nach der Hormontherapie
14.07.2010Swiss Medical Forum 2010; 10:483-485
Omlin Aurelius, Kaelin Martin, Templeton Arnoud, Jungi Manuel, Gillessen Sommer Silke, Graf Hans-Jörg, Rothermundt Christian
Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort
Cathomas R, De Santis M, Beyer J, Mayer F, Lorch A, Zaugg K, Seifert H, Shahin O, Rentsch C, Rothermundt C, Stenner F, Helbling D, Gillessen Sommer S. Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort. Swiss Med Wkly 2010; 140:356-69.
26.06.2010Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort
26.06.2010Swiss Med Wkly 2010; 140:356-69
Cathomas Richard, De Santis Maria, Beyer Jörg, Mayer Frank, Lorch Anja, Zaugg Kathrin, Seifert Hans-Helge, Shahin Osama, Rentsch Cyrill, Rothermundt Christian, Stenner Frank, Helbling Daniel, Gillessen Sommer Silke